The Middle East & Africa infectious disease therapeutics market was valued at US$ 5.72 billion in 2022 and is expected to reach US$ 7.23 billion by 2030; it is estimated to register a CAGR of 3.0% from 2022 to 2030.
Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.
According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.
According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases.
NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country.
Rising Prevalence of Infectious Disease Fuels Middle East & Africa Infectious Disease Therapeutics Market
Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women.Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.
According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.
Middle East & Africa Infectious Disease Therapeutics Market Overview
The infectious disease therapeutics market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth can be attributed to the increasing prevalence of chronic viral diseases and growing research studies across the region. Moreover, the emergence of advanced healthcare facilities is likely to propel market growth during the forecast period. Saudi Arabia is among the fastest-growing regions in the Middle East & Africa, driven by a huge population base and the increasing prevalence of infectious diseases. Tuberculosis in Saudi Arabia is spread through migrant workers and pilgrims.According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases.
NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country.
Middle East & Africa Infectious Disease Therapeutics Market Segmentation
The Middle East & Africa infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.- Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
- In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
- Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
- In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
- By country, the Middle East & Africa infectious disease therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa infectious disease therapeutics market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
5. Infectious Disease Therapeutics Market - Middle East & Africa Market Analysis
6. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Drug Class
7. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Indication
8. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Route of Administration
9. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Distribution Channel
10. Middle East & Africa Infectious Disease Therapeutics Market - Country Analysis
11. Infectious Disease Therapeutics Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- AbbVie Inc
- Astellas Pharma Inc
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- GSK Plc
- Merck & Co Inc
- Pfizer Inc
